Is Now The Perfect Time To Buy AstraZeneca plc, Greggs plc And Stanley Gibbons Group PLC?

Are these 3 stocks ripe for investment? AstraZeneca plc (LON: AZN), Greggs plc (LON: GRG) and Stanley Gibbons Group PLC (LON: SGI)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Turning companies around from disappointing financial performance to superb profitability is never an easy task. After all, there is usually a very good reason for their bottom lines falling, whether that is a change in customer tastes, a recession or poor decisions by management which have caused the business to become uncompetitive. And, even if the right strategy is put in place, it usually takes a considerable amount of time for even the best of companies to mount a successful comeback.

One stock which is very much on the up is AstraZeneca (LSE: AZN). It has endured a very challenging period of time with a number of key, blockbuster drugs coming off patent and being exposed to generic competition. However, it was a poor response by the business which led to its downfall, since it lacked a strong pipeline of new drugs to take the places of the ones which lost patent protection. Furthermore, policies such as a major share buyback were using up vital cash resources which could have been better spent on improving the company’s long term outlook.

However, under a different management team, AstraZeneca has got its house in order. It has embarked on a highly successful acquisition spree, with its sound balance sheet and excellent cash flow being used to bring on board a number of new drugs and potential treatments which, in years to come, could become blockbuster drugs for the business. And, while the company’s share price has soared by 46% since the start of 2013 (while also paying a yield of 6.1% throughout the period), its shares trade on a relatively appealing price to earnings (P/E) ratio of 15.4.

Also making a successful turnaround is high-street food business Greggs (LSE: GRG). It lost its way under previous management, with the business attempting to diversify its offering through more upmarket coffee shops and a range of chilled/frozen foods on sale in supermarkets. In other words, it appeared to lose focus on its core offering but, under a different management team, Greggs has become a more efficient and simple business. For example, it has closed unprofitable stores, improved its supply chain and focused on giving customers what they want: good value food in convenient locations.

Furthermore, today’s update from Greggs is very positive. It has reported strong sales in a low inflation environment and expects its full-year results to be ahead of market expectations. As such, its shares are up by 6% today, making it a gain of 56% since the turn of the year.

However, Greggs is likely to see margins squeezed in future years from the impact of the new living wage. And, while it already pays its staff a higher rate than the minimum wage, for a business which is focused on value it may be unable to pass all of the additional costs on to consumers.

Meanwhile, collectibles company Stanley Gibbons (LSE: SGI) appears to be in need of a turnaround, with its shares slumping by 27% today after a profit warning. It continues to struggle with a slowing Asian economy and, while it states in today’s update that its second half performance will be much better than its first, margins are coming under increasing pressure.

As a result, its short term performance is likely to be rather disappointing and its shares may continue the run which has seen them fall by 62% since the turn of the year. However, Stanley Gibbons remains a financially sound, niche business which has long term potential to recover as the world economy stabilises. And, with it having a price to book value (P/B) ratio of just 0.8, it appears to be worth buying for the long term.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Long-term vs short-term investing concept on a staircase
Investing Articles

Is now a good time to start investing in the wealth-building stock market?

The stock market is a battle-hardened builder of wealth long term. But with risks mounting, is now a good time…

Read more »

Investing Articles

£10,000 invested in red-hot Tesco shares just 1 week ago is now worth…

Harvey Jones is impressed by how well Tesco shares have defied recent stock market volatility. So can this FTSE 100…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

See the income from investing a £20k ISA in this UK stock before it goes ex-dividend on 9 April

Harvey Jones says this UK stock offers one of the highest yields on the FTSE 100. Investors need to act…

Read more »

Middle-aged Caucasian woman deep in thought while looking out of the window
Investing Articles

What’s going on with the AstraZeneca share price now?

Dr James Fox explores the recent movements in the AstraZeneca share price and evaluates whether it's still a good long-term…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

This S&P 500 stock is down 30% and the CEO just bought $10m worth of shares

Insiders only buy a stock for one reason – they expect its price to go up. So, this S&P 500…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

£5,000 invested in BAE Systems shares a month ago is now worth…

BAE Systems shares have been among the FTSE 100's best performers in recent years. The question is, can the defence…

Read more »

A senior man and his wife holding hands walking up a hill on a footpath looking away from the camera at the view. The fishing village of Polperro is behind them.
Investing Articles

Here’s how a £20k ISA could generate £7,875 in monthly passive income

Have £20,000 ready to invest? Royston Wild explains how you could put this in a Stocks and Shares ISA to…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

By April 2027, £2,630 invested in Barclays shares could be worth…

Barclays shares have been flying. But what might happen to a chunk of money invested in the bank's stock over…

Read more »